Bullish indicating open at $55-$60, IPO prices at $37
Investing.com - BTIG has lowered its price target on Humacyte (NASDAQ:HUMA) to $7.00 from $8.00 while maintaining a Buy rating following the company’s second-quarter 2025 results. Currently trading at $1.69, the biotech company, with a market capitalization of $261.53 million, appears undervalued according to InvestingPro analysis.
Humacyte reported total revenue of $0.3 million and a loss per share of $(0.24), missing BTIG and consensus estimates of $0.4 million/$1.0 million and loss per share of $(0.15)/$(0.16), respectively. InvestingPro data shows the company maintains strong liquidity with a current ratio of 3.68, though it continues to burn through cash with negative EBITDA of $103.77 million in the last twelve months.
The company sold approximately 4 commercial units of its Symvess product during the second quarter, bringing the total to an estimated 9 units in the first half of 2025. This represents a decrease from the first quarter, when the company sold approximately 5 units generating about $147,000 in revenue.
BTIG noted that July sales reached approximately $0.3 million (about 12 units), exceeding the entire first-half sales volume, suggesting momentum is beginning to build in the product launch.
Humacyte’s recent clearance on the Electronic Catalog (ECAT) has expanded Symvess availability to approximately 190 military facilities, where BTIG believes the product will have increased utility in vascular trauma cases, while other planned indication expansions into dialysis access remain on track.
In other recent news, Humacyte reported its second-quarter 2025 earnings, which fell short of expectations. The company announced an earnings per share (EPS) of -$0.24, missing the anticipated -$0.16. Additionally, Humacyte’s revenue came in at $301,000, significantly below the expected $1.01 million. These results reflect a larger-than-expected loss and a considerable revenue shortfall. The earnings report has been a point of focus for investors and analysts alike. The financial figures indicate challenges that the company is currently facing. These developments are part of the recent news surrounding Humacyte’s financial performance.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.